Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

Aspirin Reduces Colon Cancer Risk for Those with Specific Gene

April 24, 2014 10:02 am | News | Comments

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. Read more...  

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Lupin, Yoshindo Ink Joint Biosimilars Venture

April 24, 2014 10:39 am | News | Comments

Lupin Ltd. announced that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. to create a new entity, YL Biologics (YLB). Read more...             

TOPICS:

Sinovac Wins China Government Grant for HFMD Vaccine

April 24, 2014 10:28 am | News | Comments

Sinovac Biotech Ltd. announced that it has received a government grant in China for construction of the company’s dedicated production facility for its Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Read more...    

TOPICS:

Germany's Merck Posts Positive PKU Drug Results

April 24, 2014 10:12 am | News | Comments

Merck announced that the Phase 3b SPARK study has met its primary endpoint in children less than 4 years of age who have phenylketonuria (PKU). Read more...                            

TOPICS:
Advertisement

AMSBIO Expands U.S. Operations

April 23, 2014 12:58 pm | News | Comments

AMSBIO has announced the opening of a new North American headquarters with executive management facilities in Cambridge, Mass., for its U.S. subsidiary, AMSBIO LLC, recognized  as a leading company contributing to the acceleration of discovery. Read more...

TOPICS:

FDA Clears IND Amendment for Hematologic Cancer Drug

April 23, 2014 12:40 pm | News | Comments

Fate Therapeutics Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced that the FDA has cleared its IND amendment to evaluate Prohema in pediatric patients undergoing hematopoietic stem cell transplantation for hematologic malignancies. Read more...

TOPICS:

Glaucoma Adjunct Restores Vision in Blinding Disorder

April 23, 2014 12:25 pm | News | Comments

An inexpensive glaucoma drug, acetazolamide, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health. Read more...

TOPICS:

Drug Firm Exec Jailed for Insider Trading

April 23, 2014 11:58 am | News | Comments

A former pharmaceutical executive (John Lazorchak, past director of financial reporting at Celgene Corp.) has been sentenced in federal court, Newark, N.J., to 15 months in prison for his role in an insider trading scheme. Read more...

TOPICS:

Bayer's Ciprofloxacin DPI Gets Orphan Drug Status

April 23, 2014 11:41 am | News | Comments

Bayer HealthCare announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis. Read more...

TOPICS:
Advertisement

New Drugs Offer Hope for Migraine Prevention

April 23, 2014 11:11 am | News | Comments

Two new studies may offer hope for people with migraine. Both studies involve drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started. Read more...         

TOPICS:

Sales of Controversial Hep C Drug Total $2.27B

April 23, 2014 11:08 am | News | Comments

Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi - launched in the United States during December and approved in Europe in January - totaled more than $2 billion in its first full quarter on the market, and it said quarterly net income tripled. Read more...

TOPICS:

Glioblastoma Vaccine Hits Primary Endpoints in Phase 1

April 23, 2014 11:03 am | News | Comments

Immatics Biotechnologies GmbH, Cancer Research UK and Cancer Research Technology announced that they have entered a license agreement to continue developing its cancer vaccine IMA950 for glioblastoma after positive results from a Phase 1 trial. Read more...

TOPICS:

Blood Pressure Drug Prevents Epilepsy After Brain Injury

April 23, 2014 10:52 am | News | Comments

Between 10 and 20% of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy. Read more...   

TOPICS:

Bayer Submits Riociguat for PAH in Japan

April 23, 2014 10:42 am | News | Comments

Bayer HealthCare has filed riociguat for the treatment of pulmonary arterial hypertension (PAH) for regulatory approval in Japan. Read more...                               

TOPICS:

FDA Fast Tracks OncoGenex Drug for Prostate Cancer

April 23, 2014 10:38 am | News | Comments

OncoGenex Pharmaceuticals Inc. announced that the FDA has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer. Read more...

TOPICS:

Alexion's Soliris Gets EC Orphan Status for New Treatment

April 23, 2014 10:30 am | News | Comments

Alexion Pharmaceuticals Inc. announced that the European Commission has granted an orphan drug designation to Soliris (eculizumab) for the prevention of graft rejection following solid organ transplantation. Read more...          

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading